MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Sorrento Therapeutics, Inc (NASDAQ: SRNE)
Organization & Developments: Sorrento
Parents
Sorrento Therapeutics, Inc (NASDAQ: SRNE)
Children
2018: Sorrento Receives FDA Approval For ZTlido Which Had A Long Road To Approval_seekingalpha.com
2018: Sorrento Therapeutics: Insider Buying Alert!_seekingalpha.com
2019: Biotech Analysis Central Preview Series: Sorrento Therapeutics_seekingalpha.com
2019: Sorrento Therapeutics Inc. (SRNE) Soars 39.64% on March 19_www.equities.com
2020: Sorrento Therapeutics May Bring Best In Class COVID-19 Tests
2020: Sorrento_Covid Report: The Trouble With Tiny Biotech's Coronavirus Cure Claim
2020: Sorrento_How a California biotech briefly tripled its value by hyping a Covid-19 ‘cure’ – Endpoints News
2020: SRNE Stock: FDA Clearance Means It's Go Time for Sorrento Therapeutics
2021: The Case For Sorrento Therapeutics: Its Antibody Library
2022: Sorrento Therapeutics: Down The Rabbit Hole_ seekingalpha.com
2022: Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits_ seekingalpha.com
2023: 3 years after rejecting $1B buyout, Sorrento files for bankruptcy amid legal battles
Its product portfolio incorporates biosimilars, cellular therapy, immuno-oncology antibodies, and antibody-drug conjugates (ADCs).
Sorrento has established one of the most diverse antibody libraries that boasts a myriad of superior quality, fully human antibodies.
Sorrento Therapeutics, Inc. is a clinical-stage biotechnology company that makes novel immunotherapies for inflammatory, autoimmune, cancer, metabolic, and neurodegenerative maladies.
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.
The company's primary segment is related to Immune-Oncology therapeutic area while the Scilex segment is primarily concerned with the non-opioid pain management system.
To develop an intramuscular injection that can neutralize Covid-19 and its variant strains, the company got a whopping $34 million contract from Defense Advanced Research Projects Agency (DARPA) in November 2020.
Jumps
*Key People: Sorrento
Finance & Acquisitions: Sorrento